Human Prostate Tissue Lysates
Pricing |
Normal Lysates: $125/100 ug |
Tumor Lysates: $175/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Introduction:
Over 95% of prostate cancers can be classified as adenocarcinomas. In general, the degree of tumor differentiation and abnormality of histologic growth pattern directly correlate with likelihood of metastases and with death. Because of marked variability in tumor differentiation from one microscopic field to another, many pathologists will report the range of differentiation among the malignant cells that are present in a biopsy (Gleason grade).
Human Prostate Cancer Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Prostatic adenoma |
n/a |
n/a |
n/a |
M |
74 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
79 |
|
Benign prostatic fibrosis |
n/a |
n/a |
n/a |
M |
72 |
|
Prostatic fibroadenoma |
n/a |
n/a |
n/a |
M |
40 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
40 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
24 |
|
Prostatic hyperplasia |
n/a |
n/a |
n/a |
M |
65 |
|
Prostatic fibroma |
n/a |
n/a |
n/a |
M |
68 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
81 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
24 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
70 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
84 |
|
Prostatic fibroma |
n/a |
n/a |
n/a |
M |
69 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
85 |
|
Prostatic fibroma |
n/a |
n/a |
n/a |
M |
69 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
50 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
65 |
|
Prostatic hypertrophy |
n/a |
n/a |
n/a |
M |
80 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
37 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
61 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
32 |
|
Normal prostate |
n/a |
n/a |
n/a |
M |
40 |
|
Prostatic Adenocarcinoma |
1 |
n/a |
n/a |
M |
79 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
77 |
|
Prostatic Adenocarcinoma |
3 |
III |
T3aNxMx |
M |
65 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
66 |
|
Prostatic Adenocarcinoma |
1 |
n/a |
n/a |
M |
63 |
|
Prostatic Adenocarcinoma |
1 |
n/a |
n/a |
M |
76 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
66 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
80 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
71 |
|
Prostatic Adenocarcinoma |
1 |
III |
T3bN0M0 |
M |
65 |
|
Prostatic Adenocarcinoma |
1 |
n/a |
n/a |
M |
69 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
78 |
|
Prostatic Adenocarcinoma |
n/a |
n/a |
n/a |
M |
43 |
|
Prostatic Adenocarcinoma |
2 |
II |
T2N0M0 |
M |
62 |
|
Prostatic Adenocarcinoma |
3 |
III |
T3bNxMx |
M |
64 |
|
Prostatic Adenocarcinoma |
1 |
n/a |
n/a |
M |
74 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
47 |
|
Prostatic Adenocarcinoma |
3 |
n/a |
n/a |
M |
71 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
87 |
|
Prostatic Adenocarcinoma |
2 |
n/a |
n/a |
M |
71 |
References:
Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1): 58-64, 1974.
Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M: Urologic Pathology: The Prostate. Philadelphia, Pa: Lea and Febiger, 1977, pp 171-197.